Evidence mapPaperPMID 37723077Full record

ArticleRenal failure2023

Gallic acid improves the metformin effects on diabetic kidney disease in mice.

Yan Hong, Jidong Wang, Wenjuan Sun, Lai Zhang, Xuefang Xu, Kaiyue Zhang

Full text read
In one paragraph

Article in Renal failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. A Comprehensive Review of the Effects ofPreventive nutrition and food science · 2025
    Review
  5. Article
  6. Article
  7. Gallic Acid Protects from Sepsis-Induced Acute Lung Injury.Current issues in molecular biology · 2023
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yan HongDepartment of Nephrology, Jiangnan University Medical Center (JUMC), Wuxi, China.
Jidong WangDepartment of Nephrology, Jiangnan University Medical Center (JUMC), Wuxi, China.
Wenjuan SunDepartment of Nephrology, Jiangnan University Medical Center (JUMC), Wuxi, China.
Lai ZhangDepartment of Nephrology, Jiangnan University Medical Center (JUMC), Wuxi, China.
Xuefang XuDepartment of Nephrology, Jiangnan University Medical Center (JUMC), Wuxi, China.
Kaiyue ZhangDepartment of Nephrology, Jiangnan University Medical Center (JUMC), Wuxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesMetformin is an antidiabetic agent that is used as the first-line treatment of type 2 diabetes mellitus. Gallic acid is a type of phenolic acid that has been shown to be a potential drug candidate to treat diabetic kidney disease, an important complication of diabetes. We aimed to test whether a combination of gallic acid and metformin can exert synergetic effect on diabetic kidney disease in diabetic mice model.

methodsStreptozotocin (65 mg/kg) intraperitoneal injection was used to induce diabetic kidney disease in mice. The diabetic mice were treated with saline (Vehicle), gallic acid (GA) (30 mg/kg), metformin (MET) (200 mg/kg), or the combination of gallic acid (30 mg/kg) and metformin (200 mg/kg) (GA + MET).

resultsOur results demonstrated that compared to the untreated diabetic mice, all three strategies (GA, MET, and GA + MET) exhibited various effects on improving renal morphology and functions, reducing oxidative stress in kidney tissues, and restoring AMP-activated protein kinase (AMPK)/silent mating type information regulation 2 homolog 1 (SIRT1) signaling in kidney tissues of diabetic mice. Notably, the combination strategy (GA + MET) provided the most potent renal protection effects than any single strategies (GA or MET).

conclusionOur results support the hypothesis that gallic acid might serve as a potential supplement to metformin to enhance the therapeutical effect of metformin.

Indexed as

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Diabetic NephropathiesMetforminAnimalsGallic AcidMiceGallic AcidMetformindiabetes mellitusGallic acidmetforminnephropathy

Identifiers

PMID37723077
PMCPMC9987773

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.